Cancer Nanoimmunotherapy Using Advanced Pharmaceutical Nanotechnology

Li, Wei; Wei, Huafeng; Li, Huafei; Gao, Jie; Feng, Si‐Shen; Guo, Yajun

doi:10.2217/nnm.14.127

Cited by 34 publications

(23 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…tumor antigen-specific TCRs or chimeric antigenreceptor (CAR) gene-transduced blood T cells) to enable them to target cancer, and then reinfusing them, so that they can kill cancer cells [1]. Hence, cancer immunotherapy was selected as Breakthrough of the Year for 2013 by Science [3].…”

Section: Daxiangmentioning

confidence: 99%

“…The effect of traditional immunotherapy is modest, frequently due to tumor escape and resistance of multiple mechanisms [3]. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients.…”

Section: Daxiangmentioning

confidence: 99%

“…Encouragingly, some nanostructures have already been demonstrated to be applicable as a drug delivery system, and the application of nanotechnology can improve the efficacy of immunostimulatory small molecules by altering their co-localization, bio-distribution and release kinetics [5]- [7]. Extensive evidence d e m o n s t r a t e s t h a t n a n o c a r r i e r s ( i n c l u d i n g micelles, liposomes, polymer-drug conjugates, metal nanoparticles, solid lipid nanoparticles and biodegradable nanoparticles) could be used for the cellular transfer of immune effectors for active and passive nanoimmunotherapy [3]. Nanocarriers can be used to enhance cancer immunotherapy at four alternative pathways: (1) deliver cancer vaccine antigens and adjuvants to dendritic cells, (2) stimulate T cells directly as artificial antigen presenting cells, (3) concentrate immunostimulatory compounds in the immunosuppressive tumor microenvironment, and (4) deliver supportive drugs to T cells in the circulation [2].…”

Section: Daxiangmentioning

confidence: 99%

“…Nanocarriers can be used to enhance cancer immunotherapy at four alternative pathways: (1) deliver cancer vaccine antigens and adjuvants to dendritic cells, (2) stimulate T cells directly as artificial antigen presenting cells, (3) concentrate immunostimulatory compounds in the immunosuppressive tumor microenvironment, and (4) deliver supportive drugs to T cells in the circulation [2]. The smart engineering of nanocarriers based on the unique features of the tumor microenvironment and extra-/intra-cellular conditions of tumor cells can greatly tip the triangle immunobalance among host, tumor and nanoparticles in favor of antitumor responses, which shows a promising prospect for nanoimmunotherapy [3].…”

Section: Daxiangmentioning

confidence: 99%

See 3 more Smart Citations

Cancer Nano-Immunoengineering: The Marriage of Immunoengineering and Nanotechnology for Cancer Therapy

Jin¹,

Cui²

2016

Nano BioMed ENG

View full text Add to dashboard Cite

Section: Daxiangmentioning

confidence: 99%

Section: Daxiangmentioning

confidence: 99%

Section: Daxiangmentioning

confidence: 99%

Section: Daxiangmentioning

confidence: 99%

See 2 more Smart Citations

Cancer Nano-Immunoengineering: The Marriage of Immunoengineering and Nanotechnology for Cancer Therapy

Jin¹,

Cui²

2016

Nano BioMed ENG

View full text Add to dashboard Cite

“…17,18 In order to improve drug-specific accumulation in tumors, various novel stimulus-sensitive polymeric micelles were designed such as the temperature, 19 pH, 20 reduction, 21 light, 22 magnetic field, 23 and ultrasound. 24 Among these newly developed functional carriers, nanomicelles are ideal candidates for the delivery of hydrophobic shikonin.…”

Section: Introductionmentioning

confidence: 99%

Successful in vivo hyperthermal therapy toward breast cancer by Chinese medicine shikonin-loaded thermosensitive micelle

Su¹,

Huang²,

Chen³

et al. 2017

IJN

Self Cite

View full text Add to dashboard Cite

The Chinese traditional medicine Shikonin is an ideal drug due to its multiple targets to tumor cells. But in clinics, improving its aqueous solubility and tumor accumulation is still a challenge. Herein, a copolymer with tunable poly(N-isopropylacrymaide) and polylactic acid block lengths is designed, synthesized, and characterized in nuclear magnetic resonance. The corresponding thermosensitive nanomicelle (TN) with well-defined core-shell structure is then assembled in an aqueous solution. For promoting the therapeutic index, the physical-chemistry properties of TNs including narrow size, low critical micellar concentration, high serum stability, tunable volume phase transition temperature (VPTT), high drug-loading capacity, and temperature-controlled drug release are systematically investigated and regulated through the fine self-assembly. The shikonin is then entrapped in a degradable inner core resulting in a shikonin-loaded thermosensitive nanomicelle (STN) with a VPTT of ~40°C. Compared with small-molecular shikonin, the in vitro cellular internalization and cytotoxicity of STN against breast cancer cells (Michigan Cancer Foundation-7) are obviously enhanced. In addition, the therapeutic effect is further enhanced by the programmed cell death (PCD) specifically evoked by shikonin. Interestingly, both the proliferation inhibition and PCD are synergistically promoted as T > VPTT, namely the temperature-regulated passive targeting. Consequently, as intravenous injection is administered to the BALB/c nude mice bearing breast cancer, the intratumor accumulation of STNs is significantly increased as T > VPTT, which is regulated by the in-house developed heating device. The in vivo antitumor assays against breast cancer further confirm the synergistically enhanced therapeutic efficiency. The findings of this study indicate that STN is a potential effective nanoformulation in clinical cancer therapy.

show abstract

Exosomes and Nanoengineering: A Match Made for Precision Therapeutics

et al. 2019

View full text Add to dashboard Cite

Intense efforts from both scientists and physicians across Australia have been devoted onward advancing studies to fill the gap in understanding the biology and pathogenesis underlying cancer development. Exosomes are membrane-bound bio-nanoparticles secreted or released by most cells into the extracellular space. There has been an increasing interest in such bio-nanoparticles over the past 10 years, evident from the publication number of only 324 papers in 2006 to a massive increase to 4603 publications in 2018 with the search term "exosome" based on title/abstract in PubMed. Among these studies, 151 articles published from 2007 to 2018 are from Australian institutions, with 33 papers published in 2018. Such a strong surge of interest is due to discoveries that exosomes play key roles in intercellular and intertissue communication mediated by virtue of cargos contained inside the membrane-confined space. Furthermore, exosome cargos, including proteins, mRNAs and miRNAs, are linked to the Targeted exosomal delivery systems for precision nanomedicine attract wide interest across areas of molecular cell biology, pharmaceutical sciences, and nanoengineering. Exosomes are naturally derived 50-150 nm nanovesicles that play important roles in cell-to-cell and/or cell-to-tissue communications and cross-species communication. Exosomes are also a promising class of novel drug delivery vehicles owing to their ability to shield their payload from chemical and enzymatic degradations as well as to evade recognition by and subsequent removal by the immune system. Combined with a new class of affinity ligands known as aptamers or chemical antibodies, molecularly targeted exosomes are poised to become the next generation of smartly engineered nanovesicles for precision medicine. Here, recent advances in targeted exosomal delivery systems engineered by aptamer for future strategies to promote human health using this class of human-derived nanovesicles are summarized.The ORCID identification number(s) for the author(s) of this article can be found under https://doi.

show abstract

Cancer Nanoimmunotherapy Using Advanced Pharmaceutical Nanotechnology

Cited by 34 publications

References 117 publications

Cancer Nano-Immunoengineering: The Marriage of Immunoengineering and Nanotechnology for Cancer Therapy

Cancer Nano-Immunoengineering: The Marriage of Immunoengineering and Nanotechnology for Cancer Therapy

Successful in vivo hyperthermal therapy toward breast cancer by Chinese medicine shikonin-loaded thermosensitive micelle

Exosomes and Nanoengineering: A Match Made for Precision Therapeutics

Contact Info

Product

Resources

About